Tobramycine : interactions médicamenteuses

TOBI Podhaler should not be administered concomitantly with ethacrynic acid, furosemide, urea, or intravenous mannitol. (notice Tobramycine, Interactions médicamenteuses)

Drug Interactions Drugs with Ototoxic Potential (see WARNINGS ) Especially in the presence of impaired renal function, the use of parenterally administered bumetanide in patients to whom aminoglycoside antibiotics are also being given should be avoided, except in life-threatening conditions. (notice Bumétanide, Interactions médicamenteuses)

Aminoglycosides : Avoid concomitant use with aminoglycosides. (notice Carboplatine, Interactions médicamenteuses)

In vitro mixing of penicillins and aminoglycosides should be avoided during concomitant therapy and the drugs should be administered separately. (notice Dicloxacilline, Interactions médicamenteuses)

Because of foscarnet's tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B, cyclosporine, acyclovir, methotrexate, tacrolimus and intravenous pentamidine (see above) unless the potential benefits outweigh the risks to the patient. (notice Foscarnet, Interactions médicamenteuses)

TOBI Podhaler should not be administered concomitantly with ethacrynic acid, furosemide, urea, or intravenous mannitol. (notice Tobramycine, Interactions médicamenteuses)

Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as cisplatin, cephaloridine, kanamycin, amikacin, neomycin, polymyxin B, colistin, paromomycin, streptomycin, tobramycin, vancomycin, and viomycin, should be avoided (see PRECAUTIONS, Drug Interactions section). (notice Gentamicine, Mise en garde encadrée)

Concurrent and/or sequential systemic, oral or topical use of other aminoglycosides, including paromomycin and other potentially nephrotoxic and/or neurotoxic drugs such as bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin, should be avoided because the toxicity may be additive. (notice Néomycine, Mise en garde encadrée)

Because the nephrotoxic effects may be additive, the concomitant or sequential use of Pentamidine Isethionate and other nephrotoxic drugs such as aminoglycosides, amphotericin B, cisplatin, foscarnet, or vancomycin should be closely monitored and avoided, if possible. (notice Pentamidine, Interactions médicamenteuses)

THE CONCURRENT OR SEQUENTIAL USE OF OTHER NEUROTOXIC AND/OR NEPHROTOXIC DRUGS WITH POLYMYXIN B SULFATE, PARTICULARLY BACITRACIN, STREPTOMYCIN, NEOMYCIN, KANAMYCIN, GENTAMICIN, TOBRAMYCIN, AMIKACIN, CEPHALORIDINE, PAROMOMYCIN, VIOMYCIN, AND COLISTIN SHOULD BE AVOIDED. (notice Polymyxine B, Mise en garde encadrée)

Avoid concomitant use of torsemide and aminoglycoside antibiotics, if possible. (notice Torasémide, Interactions médicamenteuses)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (notice Tobramycine, Interactions médicamenteuses)

• Aminoglycosides: May lower serum calcium for prolonged periods ( 7.1 ) (notice Acide zolédronique, Interactions médicamenteuses)

However, this is of special importance in patients at risk of or having underlying renal dysfunction and patients taking concomitant nephrotoxic agents such as cyclosporine, tacrolimus, aminoglycosides, vancomycin and non-steroidal anti-inflammatory drugs [See Adverse Reactions (6.2) and Clinical Pharmacology (12.3) ]. (notice Adéfovir, Mises en garde et précautions)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (notice Tobramycine, Interactions médicamenteuses)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (notice Tobramycine, Interactions médicamenteuses)

Drug Interactions Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine. (notice Atracurium, Interactions médicamenteuses)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (notice Tobramycine, Interactions médicamenteuses)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (notice Tobramycine, Interactions médicamenteuses)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (notice Tobramycine, Interactions médicamenteuses)

Aminoglycosides: Increased potential of nephrotoxicity and ototoxicity. (notice Céfépime, Interactions médicamenteuses)

Drug Interactions As with other cephalosporins, cefotaxime may potentiate the nephrotoxic effects of nephrotoxic drugs such as aminoglycosides, NSAIDs and furosemide. (notice Céfotaxime, Interactions médicamenteuses)

If CEFOTAN® and an aminoglycoside are used concomitantly, renal function should be carefully monitored, because nephrotoxicity may be potentiated. (notice Céfotétan, Précautions)

Aminoglycosides: Increased potential of nephrotoxicity. (notice Céfoxitine, Interactions médicamenteuses)

Drug Interactions Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporin antibiotics. (notice Cefprozil, Interactions médicamenteuses)

Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (notice Ceftazidime, Interactions médicamenteuses)

Vancomycin, Amsacrine, Aminoglycosides, and Fluconazole Vancomycin, amsacrine, aminoglycosides, and fluconazole are physically incompatible with ceftriaxone in admixtures [see Dosage and Administration (2.3) ]. (notice Ceftriaxone, Interactions médicamenteuses)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (notice Tobramycine, Interactions médicamenteuses)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (notice Tobramycine, Interactions médicamenteuses)

…ciprofloxacin melphalan amphotericin B azapropazon cimetidine tacrolimus fibric acid derivatives (e.g., bezafibrate, fenofibrate) gentamicin ketoconazole colchicine ranitidine methotrexate tobramycin diclofenac trimethoprim with sulfamethoxazole naproxen vancomycin sulindac During the concomitant use of a drug that may exhibit additive or synergistic renal impairment… (notice Ciclosporine, Interactions médicamenteuses)

The safety of cidofovir injection has not been evaluated in patients receiving other known potentially nephrotoxic agents, such as intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents (see DOSAGE AND ADMINISTRATION ). (notice Cidofovir, Mises en garde)

Some examples include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ] . (notice Éfavirenz, lamivudine et ténofovir, Interactions médicamenteuses)

Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ] . (notice Elvitégravir, cobicistat, emtricitabine et ténofovir, Interactions médicamenteuses)

Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ] . (notice Emtricitabine et ténofovir, Interactions médicamenteuses)

Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, adefovir dipivoxil, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.5) ] . (notice Emtricitabine, rilpivirine et ténofovir, Interactions médicamenteuses)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (notice Tobramycine, Interactions médicamenteuses)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (notice Tobramycine, Interactions médicamenteuses)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (notice Tobramycine, Interactions médicamenteuses)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (notice Tobramycine, Interactions médicamenteuses)

Aminoglycosides or other agents that interfere with neuromuscular transmission may potentiate the effect of XEOMIN; co-administer only with caution and close observation ( 7 ) (notice IncobotulinumtoxinA, Interactions médicamenteuses)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (notice Tobramycine, Interactions médicamenteuses)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (notice Tobramycine, Interactions médicamenteuses)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (notice Tobramycine, Interactions médicamenteuses)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (notice Tobramycine, Interactions médicamenteuses)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (notice Tobramycine, Interactions médicamenteuses)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (notice Tobramycine, Interactions médicamenteuses)

Examples Cyclosporine A, trimethoprim/sulfamethoxazole, bile acid sequestrants (cholestyramine), rifampin as well as aminoglycoside, cephalosporin, fluoroquinolone and penicillin classes of antimicrobials Drugs Modulating Glucuronidation Clinical Impact Concomitant use with drugs inducing glucuronidation decreases MPA systemic exposure, potentially reducing mycophenolate… (notice Mycophénolate, Interactions médicamenteuses)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (notice Tobramycine, Interactions médicamenteuses)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (notice Tobramycine, Interactions médicamenteuses)

Patients receiving concomitant treatment of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like agents), or muscle relaxants, should be observed closely because the effect of BOTOX may be potentiated ( 7.1 , 7.4 ) (notice OnabotulinumtoxinA, Interactions médicamenteuses)

Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (notice Pipéracilline et tazobactam, Interactions médicamenteuses)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (notice Tobramycine, Interactions médicamenteuses)

Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as Rocuronium Bromide Injection include certain antibiotics (e.g., aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). (notice Rocuronium, Interactions médicamenteuses)

Caution should be exercised when using agents (e.g., aminoglycosides and amphotericin B) that are known to have a deleterious effect on renal function. (notice Sirolimus, Mises en garde et précautions)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (notice Tobramycine, Interactions médicamenteuses)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (notice Tobramycine, Interactions médicamenteuses)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (notice Tacrolimus, Mises en garde et précautions)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (notice Tobramycine, Interactions médicamenteuses)

Some examples include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.2) ]. (notice Ténofovir, Interactions médicamenteuses)

Aminoglycosides or other agents interfering with neuromuscular transmission Anticholinergic drugs Botulinum neurotoxin products Muscle relaxants Aminoglycoside antibiotics, anticholinergic agents, or any other agents that interfere with neuromuscular transmission may potentiate the effect of DAXXIFY; co-administer only with caution and close observation. (notice Toxine botulinique de type A, Interactions médicamenteuses)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (notice Tobramycine, Interactions médicamenteuses)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (notice Tobramycine, Interactions médicamenteuses)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (notice Tobramycine, Interactions médicamenteuses)

The risk is higher in older patients, patients who are receiving higher doses, who have an underlying hearing loss, who are receiving concomitant therapy with another ototoxic agent, such as an aminoglycoside or who have underlying renal impairment. (notice Vancomycine, Mises en garde et précautions)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

UNASYN and aminoglycosides should not be reconstituted together due to the in vitro inactivation of aminoglycosides by the ampicillin component of UNASYN. (notice Ampicilline et sulbactam, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

Closely evaluate the renal function of patients Examples: Aminoglycosides, amphotericin B, systemic bacitracin, cisplatin, cyclosporine, foscarnet, or parenteral vancomycin Angiotensin Converting Enzyme (ACE) Inhibitors Clinical Impact: The hyponatremic and hypotensive effects of ACE inhibitors may be diminished by the concomitant administration of aspirin due… (notice Butalbital, aspirine, caféine et codéine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

Drug Interactions Certain other antibiotics (aminoglycosides and polymyxin) have also been reported to interfere with the nerve transmission at the neuromuscular junction. (notice Colistiméthate sodique, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

Before therapy with ZEMDRI is instituted, careful inquiry about previous hypersensitivity reactions to other aminoglycosides should be made. (notice Plazomicine, Mises en garde et précautions)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

Aminoglycoside antibiotics, local and some general anesthetics, antiarrhythmic agents, and other drugs that interfere with neuromuscular transmission should be used cautiously, if at all. (notice Pyridostigmine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

The following antibiotics have been associated with various degrees of paralysis: aminoglycosides (such as neomycin, streptomycin, kanamycin, gentamicin, and dihydrostreptomycin); tetracyclines; bacitracin; polymyxin B; colistin; and sodium colistimethate. (notice Vécuronium, Précautions)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

…assess the need for additional doses of Cisatracurium Besylate Injection, and to determine whether adjustments need to be made to the dose with subsequent administration. † Examples: aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, sodium colistimethate Drug or Drug Class Clinical Implications * Succinylcholine The use of… (notice Cisatracurium, Interactions médicamenteuses)